Immunocore Could Gain Green Light For First T-Cell Receptor Drug In Early 2022
Tebentafusp Granted Rare EU Accelerated Assessment
The UK biotech is the first company to file a T-cell receptor therapy with regulators, a class with potential to hit targets unreachable for antibodies and CAR-Ts.
